Scienture (NASDAQ:SCNX – Get Free Report) issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.25) by $2.18, Zacks reports. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.96 million.
Scienture Stock Performance
Shares of NASDAQ SCNX traded up $0.37 during mid-day trading on Wednesday, hitting $4.13. 106,740 shares of the company were exchanged, compared to its average volume of 123,787. The stock has a 50 day simple moving average of $8.87 and a 200-day simple moving average of $9.29. Scienture has a 1-year low of $3.23 and a 1-year high of $65.00. The company has a quick ratio of 2.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.15. The firm has a market cap of $6.77 million, a price-to-earnings ratio of -0.08 and a beta of 3.34.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. Zacks Research upgraded shares of Scienture to a “hold” rating in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Scienture currently has an average rating of “Hold” and a consensus price target of $37.50.
Scienture Company Profile
Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.
Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).
Featured Articles
- Five stocks we like better than Scienture
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
